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Background: Insertional mutagenesis screens of retrovirus-induced mouse tumors have proven valuable in human
cancer research and for understanding adverse effects of retroviral-based gene therapies. In previous studies, the
assignment of mouse genes to individual retroviral integration sites has been based on close proximity and
expression patterns of annotated genes at target positions in the genome. We here employed next-generation RNA
sequencing to map retroviral-mouse chimeric junctions genome-wide, and to identify local patterns of transcription
activation in T-lymphomas induced by the murine leukemia gamma-retrovirus SL3-3. Moreover, to determine
epigenetic integration preferences underlying long-range gene activation by retroviruses, the colocalization
propensity with common epigenetic enhancer markers (H3K4Me1 and H3K27Ac) of 6,117 integrations derived
from end-stage tumors of more than 2,000 mice was examined.
Results: We detected several novel mechanisms of retroviral insertional mutagenesis: bidirectional activation of mouse
transcripts on opposite sides of a provirus including transcription of unannotated mouse sequence; sense/antisense-type
activation of genes located on opposite DNA strands; tandem-type activation of distal genes that are positioned
adjacently on the same DNA strand; activation of genes that are not the direct integration targets; combination-type
insertional mutagenesis, in which enhancer activation, alternative chimeric splicing and retroviral promoter insertion
are induced by a single retrovirus. We also show that irrespective of the distance to transcription start sites, the far
majority of retroviruses in end-stage tumors colocalize with H3K4Me1 and H3K27Ac-enriched regions in murine
lymphoid tissues.
Conclusions: We expose novel retrovirus-induced host transcription activation patterns that reach beyond a single
and nearest annotated gene target. Awareness of this previously undescribed layer of complexity may prove important
for elucidation of adverse effects in retroviral-based gene therapies. We also show that wild-type gamma-retroviruses
are frequently positioned at enhancers, suggesting that integration into regulatory regions is specific and also subject
to positive selection for sustaining long-range gene activation in end-stage tumors. Altogether, this study should prove
useful for extrapolating adverse outcomes of retroviral vector therapies, and for understanding fundamental cellular
regulatory principles and retroviral biology.
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The murine leukemia viruses (MLVs) are slowly-trans-
forming gamma-retroviruses that induce tumors of
hematopoietic origin upon injection into susceptible
newborn mice [1,2]. MLVs are simple retroviruses that
contain only the gag, pol and env genes flanked at both
ends by major regulatory regions, the long terminal
repeats (LTRs) composed of U3, R and U5. A hallmark of
retroviral replication is the stable integration of the ~9 kb
genome into host chromosomes as a provirus which makes
gamma-retroviral and lentiviral-based vectors attractive
gene delivery vehicles for some therapeutic applications in
human gene therapy ([3-6] for recent reviews). MLVs alter
mouse gene expression via insertional mutagenesis (IM),
which induces transcriptional or post-transcriptional de-
regulation of affected genes. The major determinants of
retroviral IM are the LTRs, which contain viral promoter
and enhancer elements in U3. Insertion of the provirus
upstream from the first exon or in early introns may
induce transcription of the target mouse gene driven by
the retroviral promoter and this is known as promoter
insertion. Transcripts may also undergo alternative splicing
resulting from the use of either proviral or cryptic intronic
splice sites, while integration in the 3′-end of a gene may
result in truncation of the native transcript due to usage
of a proviral poly (A) signal present in the LTR [3-7]. MLV
enhancer activation mutagenesis is induced by enhancer
elements present in U3, which augment transcription
from cellular promoters over long distances by recruitment
of transcription factors. IM screens based on retroviral and
transposon mouse models have proven an effective ap-
proach in identifying human cancer genes [3-6,8,9].
IM has received increased attention due to the occur-
rence of adverse events following gamma-retroviral vector-
based gene therapy to correct the X-linked severe combined
immunodeficiency disease (X-SCID) in which a lymphopro-
liferative disorder was induced in patients by activation of
the LMO2 oncogene [10-13]. In another clinical trial to
correct the X-linked chronic granulomatous disease
(X-CGD) immunodeficiency, gamma-retroviral vector
integration caused activation of MDS1-EVI1, resulting
in myelodysplastic syndrome (MDS) with transition to
acute myeloid leukemia (AML) and development of
monosomy 7 [14,15]. Therefore, understanding funda-
mental principles of retrovirus-induced tumorigenesis
including integration site preferences and mechanisms
of host sequence deregulation is vital for the improvement
of therapy safety and assessment of possible genetic dis-
ruptions in the course of treatment.
While earlier studies suggested that MLVs preferentially
target DNase I hypersensitive regions, transcription start
sites (TSSs) and CpG islands [16,17], several in vitro studies
and studies of cultured primary cells have shown that
gamma-retroviral vectors favor integration into nucleosomalDNA [18-24]. Chromatin associated with histone methyla-
tions and acetylations including H3K4Me3 and H3K27Ac/
H3K4Me1 which are common promoter and enhancer
markers, respectively [25-28], are major targets of gamma-
retroviral vector integration [22-24].
The bromodomain and extraterminal (BET) proteins
mediate MLV integration at TSSs by tethering the inte-
grase to acetylated H3 and H4 tails [29], and expression of
a BET fusion protein containing the chromatin binding
domain of the lentiviral integrase cofactor LEDGF/p75
results in retargeting of MLV to match the integration
profile of HIV [30]. While promoters and promoter-
proximal enhancers are functionally similar [31,32],
promoter-distal enhancers may enhance transcription
from thousands of bp away. One example is the distal
limb bud enhancer of mouse Shh which is positioned
1 Mb from the Shh promoter [33,34]. The mammalian
genome is demarcated into coregulated enhancer and
promoter units known as EPUs [25], and it has been
shown that proviruses positioned in c-Myb upstream
elements that coincide with enhancers in the EPU of
this gene, establish physical contact with the c-Myb
promoter through DNA looping [35]. Taken together,
this suggests that the three-dimensional structure of the
genome influences promoter-distal integration-mediated
long-range gene activation. It is currently not known if
integration outside TSSs is mediated by BET proteins or
other factors.
In the past, MLV integrations were identified using
anchored-type PCR methods and Sanger sequencing,
including e.g. a special 5′-end primer called a splinkerette,
or inverse PCR [36-38]. Next-generation sequencing (NGS)
has proven effective in the analysis of retroviral biology in
diverse contexts, including HIV-1 infection and gamma-
retroviral and lentiviral vector systems, and is commonly
coupled with anchored-type PCR to determine positions
of retroviral integration in DNA [39-46].
In this study we subjected four NMRI mouse tumors
induced upon infection with the rapid T-lymphomagenic
MLV SL3-3 wild-type strain to strand-specific and paired-
end RNA sequencing (RNA-seq) to determine retroviral
integrations genome-wide, and to identify local patterns
of retroviral IM. We then used a dataset of 6,117 SL3-3
integrations derived from lymphoid tumors of more than
2,000 mice to determine the colocalization propensity
of proviruses with ENCODE immunoprecipitation with
sequencing (ChIP-seq) enhancer and promoter markers
in vivo [25]. Our study unravels novel mechanisms of
retroviral IM involving bidirectional and tandem-type
activation patterns, as well as more complex patterns
including activation of major unannotated transcripts
and combination-type activation where transcription is
induced by promoter insertion, chimeric alternative spli-
cing and enhancer activation by a single provirus. We also
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at ChIP-seq H3K4Me1/H3K27Ac-enriched positions
irrespective of their distance to TSSs, suggesting that
insertion into cellular regulatory regions is highly specific
and subject to positive selection during tumorigenesis for
sustaining long-range gene activation.
Results
Chimeric sequencing reads expose retroviral
integration sites
In this study RNA-seq was used without specific enrich-
ment to map integrations, and simultaneously determine
transcript expression levels at sites of integration. We
made whole-transcriptome libraries of four thymic tumors
induced by wild-type SL3-3 in mice of an inbred NMRI
strain. The four tumors are referred to as 324, 327, 359
and 410. We obtained ~290 million 101-base reads
exceeding an average of ~70 million single reads per
tumor (online available sequencing data). Integrations
were mapped by analysis of 14 paired-end sequence
signatures that expose genetic structural alterations in
tumors (Additional file 1: Figure S1). We manually exam-
ined the evidence for each retroviral-mouse chimeric pos-
ition and assigned 92 integrations supported by chimeric
fusions, and 44 regions for which fusions were not directly
covered in sequencing (Figure 1A). Table 1 provides an
overview of the RNA-seq and other integration datasets
used in this study. The complete lists of integrations from
RNA-seq and the splinkerette-based PCR screen of NMRI
mice in Table 1 are provided in Additional files 2 and 3,
respectively.
We observed a proportional increase in the number of
integrations with increasing sequencing depth, and with
the exception of tumor 359, the fraction of chimeric read
pairs aligning in a direction from mouse to viral sequence,
and vice versa, were nearly evenly distributed (Figure 1A).
This indicates that both mouse and retroviral promoters
contribute to chimeric transcription in tumors. In tumor
359, the nearly one-sided distribution of chimeric read
pairs (from mouse to viral sequence) resulted from inte-
grations into growth-factor independence 1 (Gfi1), where
chimeric transcription is enhanced by high levels of mouse
transcription (described below).
Comparison of RefSeq gene annotations showed signifi-
cant overlap (P = 2.03E-30, hypergeometric probability)
(Figure 1B) of genes assigned from integrations supported
by chimeric fusions to those assigned from the conven-
tional integration datasets in Table 1. Since these datasets
comprise only 5,183 or 17% of RefSeq annotations gene
assignment from the corresponding RNA-seq integrations
is nonrandom. The distribution of the integrations with
respect to the closest genes is shown in Figure 1C. Genes
assigned from RNA-seq integrations that were not sup-
ported by chimeric fusions also showed significant overlap(P = 1.87e-08, hypergeometric probability) with genes
assigned from the conventional screens. However, the
potential risk of misassignment is higher since the exact
locations of proviruses are not known (the annotations are
available in Additional file 2).
We confirmed 59 of 92 (64%) integrations supported by
chimeric fusions in DNA analyses using PCR (described
in Methods). Since the majority of integrations that were
not confirmed obtained a minimum coverage in sequen-
cing (Figure 1E), it is possible that an unknown fraction
did not amplify due to low copy numbers. In total, 22 out
of 33 integrations that were not confirmed by DNA
analyses could be assigned to a previously tagged gene
(Figure 1D and E), while two out of the remaining 11
integrations were possibly misassigned in Figure 1B
when considering their proximity to previous integrations
(Figure 1D, purple arrows). Assuming that integrations
which were neither confirmed by DNA analyses, nor
assigned to a previously tagged gene are false-positives,
the estimated error-rate is <12%. It should be noted that
integrations supported by chimeric fusions showed a
distribution at enhancer peak midpoints comparable to
the BALB/c and NMRI integration datasets in Table 1
(described below).
We identified several integrations in RTCGD-assigned
common integration sites (CISs) showing that multiple
CISs are targeted in tumors: Arf6, Ccnd3, Chd9, Coro1a,
Frat1, Gfi1/Evi5, Hivep1, Hsp90b1, Ikzf1, Kis2, Mef2c,
Mir17, Myb, Mycn, Pvt1, Rasgrp1 and Thada (Additional
file 2). While the four tumors harbored integrations in Gfi1
and ecotropic viral-integration Site 5 (Evi5) (the Gfi1/Evi5
locus), tumor 359 contained six integrations at this locus,
four of which were positioned in sense in the 3′-UTR of
Gfi1 (Figure 1E). The expression of this gene was compar-
ably high in tumors (sequencing data available online).
The differential coverage at chimeric junctions in the Gfi1
3′-UTR in tumor 359 most likely represents the expan-
sion of distinct cellular subpopulations. Tumor 327
contained six interspersed integrations at the Gfi-1/Evi-5
locus, while tumor 410 contained two integrations at this
locus. Tumor 324 contained only a single integration at
the Gfi1/Evi5 locus however it contained two integrations
at the Myc/Pvt1 locus. We have previously shown the
occurrence of more than one integration at the same pos-
ition in the same tumor, indicating that insertion at such
positions trigger the onset of tumorigenesis and/or are fa-
cilitated by earlier stage or parallel mutations in individual
leukemias [52] (discussed below).
Novel principles of retroviral insertional mutagenesis
In the following sections we describe five novel mecha-
nisms of IM that are shown in their genomic context in
Figure 2. The activation mechanisms are distinguished
by diverse patterns of mouse transcription deregulation
Figure 1 (See legend on next page.)
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Figure 1 Mapping, annotation and distribution of integrations from RNA-seq. (A) Integration and library statistics for tumors 324 through
410 subjected to RNA-seq. Cufflinks [47] library scale factors (SF). The fraction of chimeric pairs (R1/R2) proceeding from the LTR or mouse
sequence, respectively, as well as the fraction of pairs spanning proviral-mouse junctions (fusions) are shown. The percentage of integrations
supported by fusions is shown in black while those without are shown in pink. Numbers within bars indicate the number of integrations. (B) Venn
diagram showing the overlap (P = 2.03E-30, hypergeometric probability) of genes assigned from integrations containing a chimeric fusion with
those assigned from integrations in RTCGD and the BALB/c and NMRI datasets in Table 1. (C) Distance map showing the positions of RNA-seq
integrations supported by chimeric fusions relative to nearest RefSeq gene annotation. (D) Distance map showing the distribution of RNA-seq
integrations relative to integrations from RTCGD and the BALB/c and NMRI datasets. The horizontal line marks a distance of 10 kb. This figure
shows (per integration) gene assignments common to the integration datasets, and if integrations were confirmed by DNA analyses (the numbers
in parenthesis indicate the number of integrations). Integrations marked by purple arrows may have been assigned to a different gene in (B)
(described in the main text). (E) Coverage of each integration site relative to the mean coverage of all integrations in each tumor. The minimum
coverage corresponds to a single chimeric read pair. The coverage of the integration marked by a red arrow in tumor 327 is above the mean. (*)
integrations supported by chimeric fusions and confirmed in DNA analyses. (^) integrations supported by chimeric fusions that were not assigned
to a previously tagged gene. The numbering of the integrations in C-E follows the numbering in Additional file 2.
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on opposite sides of a provirus (Figure 2A); tandem-type
activation of distal genes that are positioned adjacently
on the same DNA strand (Figure 2B); sense/antisense-
type activation of genes located on opposite strands
(Figure 2C); activation of genes that are not direct targets
of retroviral insertion (Figure 2D); combination-type IM
where enhancer activation, alternative chimeric splicing
and retroviral promoter insertion are used by a single
provirus to alter the expression pattern of a mouse gene
(Figure 2E). To confirm common activation patterns in
other tumors harboring integrations at the same posi-
tions (Table 2) we used quantitative real-time PCR
(qPCR) (Figure 3) and/or rapid amplification of cDNA
ends (RACE) (described below). Fragments per kb of
exon per million fragments mapped (FPKM) values for
transcripts at the loci in Figure 2 as well as additional
loci (described below) for individual tumors are shown
in Additional file 4.
Bidirectional activation of Klf7 and unknown RNA transcripts
Integration at the Klf7 locus induces a complex bidirec-
tional-type activation pattern where major deregulation
of mouse sequence is induced on both sides of the pro-
virus (Figure 2A). This results in transcriptional activation
of a large 165 kb region that is not annotated (dashed
line), upregulation of Klf7 as well as local activation of
mouse sequence at the provirus (red arrow). The Klf7
locus contains two integration clusters one of which is
positioned ~35 kb downstream of Klf7 while the other isTable 1 Retroviral integration datasets used in this study
Integration dataset Method Mod
RNA-seq RNA-seq MLV
*BALB/c and NMRI Splinkerette-PCR MLV
**RTCGD Mixed Mixe
(*) This dataset contains the combined number of unique integration coordinates f
screen provided in Additional file 3. (**) The Retrovirus and Transposon tagged Canlocated in the first intron of the gene. Klf7 was found
consistently overexpressed in tumors harboring proviral
insertions (Figure 3A) however activation of the 165 kb
region was restricted to two tumors (324 and 2110) that
contained in sense integrations in the downstream cluster
(Figure 4A). Therefore, activation of the 165 kb region
appears to be dependent on the orientation of proviruses
in the downstream cluster.
To determine whether the tumors shared common
transcripts in the unannotated region, they were subjected
to 5′-RACE which resulted in the identification of several
unknown transcripts initiating at alternative start sites
(Figure 4A). The longest transcript spanned ~90 kb within
the activated region, while one transcript resulted from
five splicing events. We did not identify any similarity hits
in common gene or RNA databases (data not shown),
suggesting that the transcripts are either random products
or perhaps the remains of a gene that has lost sequence
similarity to any known gene.
In principle, bidirectional activation could be thought to
originate from the transcriptional activities of both LTRs
of an intact provirus. However, based on RNA-seq chimeric
transcription was only detected at the 3′-LTR/mouse junc-
tion, proceeding in a direction opposite to that of Klf7 and
the unannotated 165 kb region (Figure 4A). Therefore,
transcription is induced locally by retroviral promoter
insertion, while Klf7 and the 165-kb region appear to be
activated by enhancer activation mutagenesis.
Concurrent transcription from both LTRs was observed
at other loci, including e.g. the Tmem30b/Prkch locusel No. integrations Reference
SL3-3 136 Additional file 2
SL3-3 6117 [48-50]
d 6749 [51]
rom a previously published screen of BALB/c mice as well as the NMRI mouse
cer Gene Database.
Figure 2 (See legend on next page.)
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Figure 2 Novel mechanisms of retrovirus-induced transcription activation in mouse tumors. Deregulations are shown using normalized
transcription coverage as BedGraphs [53]. Coverage on the plus and minus strand is colored red and blue, respectively. The upper panel in each
subfigure (A-E) shows the transcription profile of a tumor containing a provirus. The lower panel shows the mean coverage of tumors without
known integrations at the loci shown. Horizontal green lines mark integration clusters, and the number of proviruses from RTCGD and the BALB/c
and NMRI datasets as well as the sizes of clusters are indicated. Vertical green arrows mark positions of proviruses identified in RNA-seq and
orientations are indicated by black arrows. The deregulations in subfigures A, C and E are shown in detail in Figure 4. (A) Bidirectional activation.
Integration induces upregulation of Klf7, activation of a large 165 kb unannotated region (dashed line), and local transcription activation at the
provirus (red arrow). (B) Tandem-type activation. Integration at Ccr9 activates Lztfl1 and Slc6a20a, which are positioned adjacently on the DNA
minus strand, as well as transcription of opposite polarity in the region in between these two genes (red arrow). (C) Sense/antisense activation.
Integration downstream of Syn2 activates transcription from both DNA strands resulting in expression of non-coding AK038749 (red arrow) and
Syn2. (D) Activation of genes that are not targets of integration. Col4a5 functions as a hotspot for retroviral integrations that activate expression
of the distal gene Irs4, without affecting expression of Col4a5 itself. Integration clusters marked with arrow heads indicate that proviruses share
the same orientation. (E) Combination-type activation. Enhancer activation mutagenesis, promoter insertion and alternative splicing are used
simultaneously by a single provirus to alter the expression pattern of Celf2. The red arrow marks increased transcriptional activity in the intron
containing the provirus (described in the main text).
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[54]) and retroviral promoter insertion by the 5′-LTR
and 3′-LTR, respectively, was detected by RNA-seq and
5′-RACE (Additional file 1: Figure S2). Integration at
this locus also results in bidirectional mouse sequence
activation, including transcriptional activation of unan-
notated sequence. Other loci for which unannotated
transcripts were detected are described below.Table 2 Integration sites at Syn2, Klf7, Slc6a20a/Lztfl1/
Ccr9, Celf2 and Col4a5/Irs4 in tumors from BALB/c and
NMRI mice
Tumor number and integration cluster Integration site
BALB/c




604 (Klf7, downstream) chr1:64047271
672 (Irs4, upstream) chrX:138281270
759 (Irs4, upstream) chrX:138295736
760 (Irs4, upstream) chrX:138296394










This table lists integrations in other tumors from splinkerette-based BALB/c
and NMRI mouse screens that were subjected to qPCR analysis and/or RACE.
Integration clusters are shown in Figure 2.Integrations at Ccr9 tandem-activate Lztfl1 and Slc6a20a
We observed retrovirus-induced activation of independent
transcripts at other loci including Slc6a20a/Lztfl1/Ccr9 and
Syn2/AK038749 (described below). Integration at Ccr9
induces tandem-activation of the distal genes Slc6a20a
and Lztfl1 which are located adjacently in the same
orientation (Figure 2B), as well as increased transcription
of opposite polarity (red arrow). The Slc6a20a/Lztfl1/Ccr9
locus contains five integrations clustered in a region im-
mediately upstream of Ccr9. Therefore, based on closest
distance, Ccr9 would be expected to be a target of retro-
viral IM. However, we did not find this gene to be system-
atically deregulated in tumors suggesting that Ccr9 is not
activated by proviruses (Figure 3B). SLC6A20 encodes an
amino acid transporter, and is duplicated in mice, i.e.
paralogues Slc6a20a and Slc6a20b [55]. Slc6a20b was not
deregulated in any of the tumors harboring integrations at
Ccr9 (data not shown).
Therefore integration at Ccr9 activates Slc6a20a and
Lztfl1, exclusively, in three independent tumors analyzed.
We speculate if the tandem-type activation pattern is
induced by integration into a shared regulatory region
through which proviruses can deregulate both Slc6a20a
and Lztfl1. The regulation of genes through shared en-
hancers has been described previously and appears to
be a regulatory principle that is applicable genome-
wide [25,56,57].
Sense/antisense activation of Syn2 and non-coding
AK038749
The sense/antisense activation mechanism at Syn2/
AK038749 induces expression of the brain genes Syn2
and non-coding AK038749 located in opposite orientation
(Figures 2C and 3C). In human glioblastoma multiforme,
SYN2 and TIMP4, a metalloproteinase-encoding gene lo-
cated within an intron of SYN2, are subjects to reciprocal
deregulation [58]. We did not detect Timp4 expression in
any tumor by qPCR analysis using three different primer
Figure 3 The transcriptional deregulations are common to other tumors containing proviruses at the same positions. (A-E) Reverse
transcription (RT)-qPCR analyses including other tumors harboring integrations at deregulated loci. Tumors subjected to RNA-seq are colored
green, and black arrow heads mark those that were found to contain a provirus at each of the loci. Other tumors of spleen and thymus from the
NMRI dataset are shown in blue and red, respectively, while tumors from the BALB/c dataset are shown in black. As control, tumors from the
same mouse strain and tissue were used without known integrations at the loci shown. It should be noted that the measurements for NMRI
thymic reference tumors are shown individually, while the average of measurements is shown for NMRI and BALB/c splenic reference tumors,
and these are marked as controls in the figure. (N) indicates that the Ct value was above a threshold of 30 cycles.
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AK038749 by 5′-RACE (Figure 4B). Interestingly, the
integrations at Syn2/AK038749 are located in an enhan-
cer region marked by the histone marker H3K4Me1 that
is coregulated with the Syn2 promoter, marked by
H3K4Me3 and H3K4Me1, in mouse cerebellum and
cortex [25] (Figure 4B). Since the AK038749 and Syn2
transcription initiation sites are positioned only ~200 bp
from each other, it is possible that proviruses activate a bi-
directional mouse promoter. In fact, promoters of manycoding genes transcribe non-coding RNAs in the opposite
direction [59].
We have previously reported on the activation of
neuronal neurogranin (Nrgn) in T-cell lymphomas in-
duced by SL3-3 integration in the Esam/Vsig2/Nrgn/
Siae/Spa17 locus where the Nrgn expression level in
lymphoid tumors corresponded to brain levels [60]. There-
fore, the deregulation pattern suggests that enhancer-
promoter associations in mouse lymphomas, which are
normally active in brain, are reinstated following retroviral
Figure 4 (See legend on next page.)
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Figure 4 Details of the bidirectional, sense/antisense and combination-type mechanisms at Klf7, Syn2/AK038749 and Celf2. (A) Close-up
of the Klf7 downstream integration cluster. Three integrations are located in this cluster including one determined by RNA-seq in tumor 324 and
two from the BALB/c mouse screen, one of which is positioned in the opposite orientation (604). RACE products obtained from tumors 324 and
2110 in the activated unannotated region are shown. At the 3′-LTR of the provirus in tumor 324 transcription proceeds in a direction from viral to
mouse sequence (red arrow) showing that transcription is activated by promoter insertion at the integration site. (B) Close-up of the sense/anti-
sense activation mechanism of AK038749 and Syn2. The proviruses are located in an H3K4Me1-enriched enhancer region in the Syn2 EPU [25],
located ~11 kb from the Syn2 promoter (H3K4Me1/H3K4Me3-enriched region). The proximity (~200 bp) of Syn2 and AK038749 suggest activation
through a bidirectional promoter. AK038749 expression was also confirmed by RACE. (C) The Celf2 intronic integration cluster contains five integrations
in tumors from either RNA-seq (410) or the BALB/c mouse screen. In 410 the provirus is integrated ~25 kb from the other proviruses including the
provirus in tumor 128 that was subjected to qPCR analysis (described in the main text). (D) The figure shows an alignment resulting from remapping
of chimeric reads. Activation of Celf2 involves a combination-type mechanism including promoter insertion, enhancer activation and alternative
(chimeric) splicing. The non-chimeric upstream transcript variant, and initiation of transcription in the 3′-LTR, was confirmed by 5′-RACE. The stippled
angled lines indicate shortening of the intron. The curved bold arrow illustrates retroviral enhancer activation. Intronic splice donor (iSD). Transcription
start site (TSS). In A-D, the proviruses identified in RNA-seq are shown in black, and angled arrows denote the 5′-LTR. In A-C, tumor numbers are
indicated and the approx. integration positions.
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brain genes at this locus.
Integrations at the Col4a5/Irs4 locus activate Irs4 only
The activation pattern at the Col4a5/Irs4 locus shows
resemblance to deregulations detected at the Ccr9 locus.
However, in this case one gene (Col4a5), functions as a
hotspot for retroviral integrations that induce expression
of another distal gene (Irs4) (Figure 2D), without affect-
ing the expression of Col4a5 itself in any tumor analyzed
(Figure 3D, and data not shown). The Col4a5/Irs4 locus
contains in the excess of 30 integrations delimited by
two major clusters that intersect at Irs4. Col4a5 contains
10 of these sites, one of which is located more than
220 kb from the Irs4 promoter. The finding that IRS4
but not COL4A5 activation in T-ALL involves translocation
of both genes to the T-cell receptor beta locus [61] is
particularly interesting considering that insertion of the
retroviral enhancer mimics such oncogenic rearrange-
ments. We detected an activation pattern at the Wwox
locus fairly similar to the patterns observed at the Klf7,
Col4a5/Irs4 and Ccr9 loci (Additional file 1: Figure S3).
Integration into Wwox induces increased expression of
Wwox as well as activation of distal Maf and unannotated
mouse sequence of opposite polarity both of which are
located outside the actual integration target.
Celf2 is activated by a combination-type mechanism of
insertional mutagenesis
The deregulation shown in Figure 2E results from a
combination-type activation mechanism where several
modes of IM are employed by a provirus to alter the ex-
pression of Celf2, whereby a non-chimeric transcript vari-
ant initiating from a far upstream position is activated,
including also increased transcription in the provirus-
containing intron (red arrow).
Remapping of chimeric sequencing reads against the
Celf2 reference sequence containing the integrated pro-
virus made it possible to link upstream and downstreamCelf2 sequence to the provirus (Figure 4D). RNA splicing
is mediated by the viral env splice acceptor site, and in-
volves three splice donor (SD) sites: the canonical SD
located ~39 kb upstream from the insertion site; intronic
iSD1 and iSD2, located ~38 and ~2 kb from the integra-
tion site, respectively. We confirmed splicing between the
canonical SD site and the env splice site by RT-PCR and
Sanger sequencing (data not shown). In the 3′-end of
Celf2, splicing is mediated by iSD3 and iSD4, located
15 bp and 180 bp from the integration site, respectively.
The coverage by sequencing reads at the 3′-LTR/mouse
junction indicated that Celf2 is also activated by retroviral
promoter insertion. Transcription initiation at the canon-
ical U3/R position was confirmed by 5′- RACE as shown
in Figure 4D.
We wanted to confirm the activation pattern in other tu-
mors containing proviruses in the Celf2 integration cluster
(Figure 4C). Due to inadequate tumor tissue the analysis in-
cluded one tumor (128) in which the provirus is integrated
in the opposite orientation. In this tumor only the 3′-end
transcript levels were increased, showing that no transcript
variant is expressed (Figure 3E). The implications of alter-
natively spliced variants of the CELF/Bruno-like family
members is not fully understood, however differential ex-
pression of Celf2 isoforms has been related to separate tis-
sues, as well as fetal versus adult developmental stages [62].
Since, the tumors originate from similarly-aged adult mice
(described in Methods) the non-chimeric variant initiating
at a far upstream position in 410 is most likely induced by
retroviral enhancer-activation and not a developmentally
regulated difference. The lack of 5′-end activation in tumor
128 is possibly attributable to mouse strain or tissue differ-
ences and/or to the different position and orientation of the
provirus in this tumor.
Long-range IM is sustained by integration into enhancers
in end-stage tumors
Gamma-retroviral vectors show a strong propensity for
insertion into nucleosomal DNA, and in this study the
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integration clusters was examined to determine epigenetic
features underlying possible long-range gene activation
in end-stage tumors. We exploited publically available
ENCODE ChIP-seq data from Ren’s laboratory [25]
(Additional file 1: Figure S4) and major splinkerette-based
PCR integration datasets derived from tumors of more
than 2,000 BALB/c and NMRI mice (Table 1). To account
for possible bias introduced by genomic regions contain-
ing high numbers of integrations a supplementary reduced
dataset was also analyzed which excluded highly tagged
regions (described in Methods).
We found that the integrations were distributed in
clusters peaking at immediate (~1,000 bp), intermediate
(~8 kb) and distal (>10 kb) positions relative to UCSC
TSSs (Table 3 and Additional file 1: Figure S5). Thus the
majority of proviruses are not located in the immediate
vicinity of TSSs. The enhancer-colocalization analyses
are summarized in Table 3. The far majority of integrations
colocalize with regions enriched in H3K4Me1 and/or
H3K27Ac irrespective of their distance to TSSs, while the
fraction of integrations colocalizing with the promoter
marker H3K4Me3 decreases as expected.
We determined integration-enrichments of promoter-
distal integrations at ChIP-seq peaks (Figure 5), and ob-
served strong enrichments at H3K4Me1, H3K27Ac and
H3K4Me3 regions of lymphoid tissues compared to ran-
dom (P < 0.001 for all enrichments shown, described in
Methods). The chromosomal distribution of integrations
colocalizing directly in Figure 5 is shown in Additional
file 1: Figure S6. At a distance of 5,000 bp from the junc-
ture of ChIP-seq peaks the sequential decrease in coloca-
lizing integrations was nearly proportional to random forTable 3 Wild-type MLVs show a strong propensity for








Complete (n = 6117) 1602 (26%) 1186 (29%) 3329 (54%)
Median distance (bp) 868 5872 33169
H3K4Me1/H3K27Ac 1494 (93%) 1062 (90%) 2757 (83%)
H3K4Me3 902 (56%) 164 (14%) 479 (14%)
Reduced (n = 2127) 604 (28%) 348 (16%) 1175 (55%)
Median distance (bp) 800 5924 37532
H3K4Me1/H3K27Ac 551 (91%) 272 (78%) 803 (68%)
H3K4Me3 438 (73%) 59 (17%) 137 (12%)
Summary of the colocalization-analyses between retroviral integrations in tumors
and ChIP-seq enhancer (H3K4Me1 and H3K27Ac) markers. The far majority of
integrations are located at intermediate and distal positions relative to TSSs. The
median distance to TSSs of integrations in each cluster is shown, as well as the
total number of integrations that colocalized with ChIP-seq markers from thymus
and spleen, combined. Statistics concerning the H3K4Me3 marker shows
integrations that also colocalized with enhancer markers.markers including H3K4Me1 and the insulator CTCF
(data not shown), as a result of the larger amount of the
genome these markers comprise when extended to 5,000 bp
(Figure 5). Considering direct overlaps, the integration en-
richments reached as high as ~50 and ~30-fold (H3K27Ac)
for the complete and reduced integration sets, respectively,
showing that proviruses target enhancers directly. In total
2,757 of 3,329 (83%) promoter-distal integrations were posi-
tioned at enhancer markers of the lymphoid tissues, while
the number for the reduced dataset was 803 of 1,175 (68%)
(Table 3). The distribution of promoter-distal integrations
relative to specific ChIP-seq enhancer markers is shown in
Additional file 1: Figure S7.
We observed consistently lowered enrichment of inte-
grations at enhancers of brain indicating that retroviral
integration targets enhancers tissue-specifically, and there-
fore the enrichments in most cases reflect integration into
enhancers that are common to brain and the lymphoid
tissues (data not shown). The distribution of promoter-
distal integrations with respect to the midpoints of
H3K4Me1 and H3K27Ac ChIP-seq peaks shows that
the proviruses form a dense cluster peaking at ~800 bp
in case of lymphoid enhancers (i.e. spleen and thymus),
while the distribution is markedly distorted in case of brain
enhancers (i.e. cortex and cerebellum) (Figure 6).
Considering overlapping integrations in Table 3 at inter-
mediate and distal positions, ~12-17% of the integrations
overlap both H3K4Me1/H3K27Ac and H3K4Me3 markers.
Enrichment of both enhancer and promoter markers may
be caused by physical interaction between these regulatory
elements as predicted by DNA looping, whereby the his-
tone modification is assigned to the interacting region
[63-65]. It could also represent regions at unannotated
TSSs, where proviruses are located at promoters and
promoter-proximal enhancers resulting in a colocalization
pattern similar to the promoter-immediate integrations in
Table 3.
Discussion
In this study we used RNA-seq and ENCODE ChIP-seq
data to determine positions of integration, local patterns
of mouse sequence deregulation and integration-enhancer
colocalization in end-stage tumors induced by the SL3-3
retrovirus. We mapped 136 integrations in only four
tumors. 59 out of 92 (64%) integrations supported by
chimeric fusions were confirmed by DNA analyses
(Figure 1D and E), while the majority of these (~90%)
showed an expected distribution close to enhancer mid-
points (Figure 6). While the number of integrations in
only four tumors may seem high comparably high numbers
of integrations in transposon and retroviral tumor models
have been reported previously [45,66]: e.g. deep sequencing
analysis of mouse mammary tumor virus (MMTV)-in-
duced tumors, revealed an average of 27 integrations per
Figure 5 Integrations are highly enriched at enhancers. Integration-enrichment analyses of promoter-distal integration sites with enhancers
from thymus, spleen and brain including also the insulator CTCF and promoter marker H3K4Me3. The number associated with each bar indicates
the absolute number of integrations that colocalized with a given ChIP-seq marker. We defined direct colocalization based on extension of ChIP-seq
peaks by 1,250 bp (described in Methods). The enrichments shown were highly significant compared to random (P < 0.001). The lower panel shows
the percentage of the genome that the ChIP-seq features comprise including sequence extensions up to 5,000 bp.
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cluding integrations supported by only a single chimeric
sequencing read [45].
We cannot completely exclude that some insertions
that had low coverage in RNA-seq may represent endogen-
ous false-positives even-though they were unique for each
tumor. We anticipate that factors such as viral mutation
and/or recombination during tumorigenesis may compli-
cate validation of genuine integration events, and would
therefore require optimization of PCR conditions and
cloning of bands that differ from an expected size. Mutant
viruses were indeed detected in this study by Sanger se-
quencing including several 72-bp repeat variants of SL3-3
which are known to accumulate in end-stage tumors
[67,68] (data not shown). MLVs also frequently recombine
with endogenous sequences to generate replication-
competent derivative viruses which add to the complexity
of MLV-induced tumors [69,70].
The majority of integrations could not be correlated
with local transcriptional activation by Cufflinks differential
expression analysis (online available sequencing data) using
known gene annotations though infrequent activation ofmouse (unannotated) sequence was observed at several
positions as described throughout this manuscript. We
have previously shown that integration into major CISs,
including Myc and Rasgrp1, does not consistently induce
measureable changes in transcript levels, indicating that
deregulations may be imposed post-transcriptionally, in
some cases [52]. This could happen following integration
within a gene where premature polyadenylation induced
by the retroviral poly (A) signal results in a truncated tran-
script and a protein with possibly altered function rather
than increased gene expression, reviewed in [4,5]. In
addition, searching for disrupted target regions is also
complicated by the fact that deregulations may be im-
posed over long distances. Alternatively, subpopulations
of cells that constitute a minor fraction of clonal tumors
may become out-averaged in RNA-seq, thereby masking
events of retrovirus-induced transcription activation.
We found multiple integrations in the same loci, and
in the same tumors, including Gfi-1/Evi-5 and Myc/Pvt1.
The probability of finding multiple integrations in the
same region in one tumor by chance is exceedingly small.
Therefore, integrations into such positions are either
Figure 6 The colocalization of integrations with enhancers is tissue-specific. The figure shows the distribution of promoter-distal integrations
relative to enhancer midpoints determined from lymphoid (i.e. spleen and thymus) H3K4Me1 and H3K27Ac ChIP-seq peaks. The results from H3K4Me1
and H3K27Ac control datasets from brain (i.e. cerebellum and cortex) shows a substantial distortion in the distribution of integrations relative to
enhancer midpoints. The RNA-seq integrations supported by chimeric fusions show a tissue-specific distribution that is comparable to the larger
integration sets.
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dependent manner. An example is LMO2 and IL2RG
cooperation in leukemia cases among X-SCID patients
where insertional mutagenesis of LMO2 results in an
increased growth advantage in the presence of IL2RG
[71,72]. Therefore, earlier stage or parallel mutations may
predispose progenitor cells for gaining an even further
growth advantage following insertion into certain loci.
Integration into CISs is commonly considered important
as such integrations should mark disruptions that triggered
the onset of tumorigenesis in progenitor cells [73], and in
this study numerous integrations in RTCGD-assigned CISs
were detected e.g. Ccnd3, Frat1, Gfi1/Evi5, Myb and Myc/
Pvt1 (Additional file 2). Cancer genomes frequently acquire
mutations that alter disease progression and become sub-
ject to purifying selection in late stages of tumorigenesis
[74-76] suggesting that integrations in subsidiary loci may
contribute to progression rather than onset.The human orthologs of the genes described in this
study are implicated in cancer (Figure 2 and Additional
file 1: Figures S2-S3 which show deregulations of the
Prkch and Wwox loci, respectively). Elevated levels of the
transcription factor KLF7 is associated with minimal re-
sidual disease and relapse following chemotherapeutic
treatment of childhood acute lymphoblastic leukemia
(ALL) and KLF7 also promote early T cell survival [77,78].
SYN2 encodes a neuronal phosphoprotein (Synapsin 2)
and is deregulated in human glioblastoma multiforme and
breast cancer [58,79]. As described already, IRS4 is ac-
tivated in T-ALL following COL4A5/IRS4 translocation
involving the T-cell receptor beta locus [61]. The
CUGBP-ETR3-like factors and Bruno-like (or CELF/
Bruno-like) family of RNA-binding proteins regulate
RNA splicing, translation and mRNA stability. The
family comprises six members including CELF2, which
functions as a tumor suppressor in colon cancer [80].
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on human chromosome 14 have been implicated in
brain and breast cancer, respectively [81,82]. SLC6A20,
LZTFL1 and CCR9 are located on 3p21.3 in a region
that is often found eliminated in tumors, referred to as
CER1 (commonly eliminated region 1). Chromosome 3
abnormalities have been proposed to mediate tumor
formation due to loss of putative tumor suppressor genes
[83-85]. WWOX also functions as a tumor suppressor in
cervical cancer where it induces apoptosis and inhibits
proliferation [86]. Although such insertional activation of
tumor suppressors appears at least multifaceted, tumori-
genesis may be augmented by overexpression of tumor
suppressors which themselves may also exhibit oncogene
properties context-dependently [87,88].
It has become widely established that retroviral vector
integration favors nucleosomal over naked DNA, including
the epigenetic promoter and enhancer markers H3K4Me3
and H3K4Me/H3K27Ac, respectively [18-24]. Importantly,
the studies by De Rijck et al. and Sharma et al. have ex-
posed a fundamental mechanism for integration of MLVs
at TSSs mediated by BET proteins [29,30]. Therefore, BET
proteins appear to form the MLV counterpart of HIV
LEDGF/p75. These studies are particularly interesting
with respect to understanding fundamental integration
site selection patterns, as well as the underlying chromatin
structure that promotes host transcription activation by
an integrated retrovirus. While the majority of MLVs do
not target TSSs it is currently not known whether BET
proteins perform a universal function in directing provi-
ruses to distal regions.
Short-term models provide limited information, if any,
on the selection pressure during tumorigenesis, and in
our study integration-enhancer colocalizations in end-stage
tumors from more than 2,000 mice was examined. We
found that ~45% of the integrations were concentrated in
clusters at immediate and intermediate distances from
TSSs, while the remaining integrations were dispersed
throughout an extended promoter-distal cluster (Table 3
and Additional file 1: Figure S5). We found that proviruses
located promoter-distally showed a strong propensity for
integration at enhancers (83%) comparable to integrations
positioned in closer vicinity to TSSs (~90%), and this
tendency was also confirmed in a reduced integration
dataset where colocalization is not biased by highly
tagged genomic regions (Figure 5 and Table 3). Consid-
ering that ~50% of ENCODE H3K4Me1 and H3K27Ac
ChIP-seq sequence of spleen and thymus (together
comprising ~181 Mb in total) are located promoter dis-
tally [25] (i.e. beyond 10 kb from UCSC TSSs [89]), the
proportion of colocalizing integrations in promoter-distal
regions, as well as the dense clustering of integrations at
enhancer midpoints (Figure 6) accentuates that enhancers
are indeed major targets of MLV integration in tumors.Our results are comparable to the studies by De Ravin
et al. [24] and LaFave et al. [22], where it was found
that ~87% of vector integrations in CD34+ cells overlap
H3K4Me1-enriched ChIP-seq peaks throughout the gen-
ome [24], and that integration is driven by promoters and
strong enhancers in human HepG2 and K562 cells [22].
We found that a considerable fraction of proviruses
did not directly target enhancers rather they appeared
positionally offset or scattered randomly in the genome
(Figures 5 and 6). For the reduced dataset offset integra-
tions accounted for 32% of all promoter-distal integrations,
and 22% in case of intermediately positioned proviruses
(Table 3). The integration pattern is likely influenced by the
chromatin state of individual end-stage tumors [90,91], and
therefore it is difficult to estimate an absolute fraction of in-
tegrations that target enhancers which optimally requires
the sequencing of hundreds of tumors in this particular
case. Considering the looping model in which a promoter-
distal enhancer is brought into proximity of a promoter,
perhaps positional offsets or displacements of retroviral in-
tegrations reflect local structural features of the genome
whereby the LTR becomes favorably positioned for inter-
action with a host promoter. Taking into account the size
of a provirus or a retroviral vector, it seems plausible that
some degree of local structural reorganization of the gen-
ome should accompany integration. In the study by Zhang
et al. [35] the authors observed positional expansion,
comprising several kb, of enhancers (H3K4Me1) in tumor
cells containing proviruses at the c-Myb locus. It would
be interesting to address at a large-scale how the local
chromatin environment changes in response to retroviral
integration in tumors, as well as determine BET protein
binding sites genome-wide. This should show if BET
tethering comprises a mechanism for integration outside
TSSs, and possibly also account for integrations offset
from enhancers.
In its basic form, a retroviral vector contains a thera-
peutic gene in place of the gag, pol, and env genes, and
is delivered in the form of a replication-defective virus
particle. Although vector-based treatments have proven
highly effective in human clinical trials IM constitutes a
major safety concern due to the development of leukemias
in a minority of patients following treatment of SCID and
CGD [10-15] (described above). In this study we have ex-
posed several novel principles of gamma-retroviral-induced
deregulations which altogether share a prominent complex-
ity that reaches beyond any previously described disruption
(Figure 2 and Additional file 1: Figures S2-S3).
We have shown several examples where more than a
single gene is subject to activation from the same or oppos-
ite DNA strands including both proximal genes and genes
whose initiation sites are positioned distantly from each
other (the AK038749/Syn2 and Slc6a20a/Lztfl1/Ccr9 loci).
We have shown that unannotated RNAs are transcribed at
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(the Klf7, Tmem30b/Prkch and Wwox loci), and that
the provirus may activate transcription outside the actual
gene in which it is integrated (the Col4a5/Irs4 and Wwox
loci). We have also shown occurrences of combination-
type activation patterns where retroviral promoter inser-
tion and enhancer activation mutagenesis are employed
by a provirus to alter the expression of a single gene
(Celf2) as well as genomic regions outside genes (the Klf7
and Tmem30b/Prkch loci).
It may seem counterintuitive that retrovirus-induced
deregulations should in general be restricted to a single
mode of mutagenesis however there is a remarkable
absence of studies reporting the use of combination-type
activation mechanisms. One reason could be that it is
difficult without prior knowledge to dissect deregulations
involving chimeric and non-chimeric transcripts, respect-
ively, to the overall expression pattern at a target locus
considering also (1) transcription from the non-infected
allele, and (2) unannotated transcripts. We believe that
combination-type deregulation may represent a more
general mechanism exposed by whole-transcriptome
RNA-seq in our study.
The promoters of many coding genes transcribe non-
coding RNAs in the opposite direction, and are therefore
bidirectional per se [92], and in cancers, non-coding RNAs
specific for certain malignant phenotype as well as pseudo-
genes are commonly expressed [93,94]. Moreover, regula-
tion through enhancer-promoter interaction is not strictly
pairwise, rather enhancers may be shared between separate
promoters to intricately coregulate the expression of more
than one gene [25,56]. Enhancers may contribute to the
establishment of a intra and interchromosomal three-
dimensional regulatory networks [95], and they may also
be positioned in genes located adjacently to the genes that
they regulate [96]. Noncoding intergenic transcription
may regulate nearby protein-coding genes and an L1 LINE
at AZU1 provides an example where expression of this
non-LTR retrotransposon correlates with the expression
of multiple surrounding genes in addition to AZU1 [97].
Considering the human globin locus, an ERV-9 LTR-
element modulates long-range transcription factor occu-
pancies at multiple cis-linked genes thereby coordinating
gene switching during hematopoiesis, and it also activates
intergenic RNAs at low levels as a result of transient DNA
looping with multiple intergenic sites [98]. Therefore, at
least for retrotransposons transcriptional activities are
sustained which present a complexity comparable to the
transcription patterns in MLV-induced tumors.
Taken together the deregulations described by us comply
with emerging principles of complex higher-order genome
regulation and show that MLVs have evolved to hijack such
routes to activate multiple regions resulting in complex and
long-ranging deregulations that are difficult to evaluateusing conventional methods. Our analyses of integration-
enhancer colocalizations in tumors also strongly support
such models. Therefore, we anticipate that retrovirus-
induced deregulations of equivalent or similar complexity
are broadly applicable to other loci throughout the
genome.
Conclusion
The analysis of MLV-induced mouse tumors using RNA-
seq has revealed novel mechanisms of retroviral insertional
mutagenesis resulting in deregulations that reach beyond a
single and nearest annotated gene target. Awareness of this
previously undescribed layer of complexity regarding host
sequence activations may prove important for elucidating
adverse effects in retroviral-based gene therapies. We have
also shown that wild-type gamma-retroviruses are posi-
tioned at enhancers of lymphoid tumors irrespective of
their distance to TSSs, showing that insertion into regula-
tory regions is highly specific and also subject to positive
selection during tumorigenesis. This suggests a mechanism
whereby the provirus exploits the higher-order genome reg-
ulatome for sustaining long-range deregulations in tumors.
This study should prove useful for extrapolating adverse
outcomes of retroviral vector therapies, and for under-
standing fundamental cellular regulatory principles.
Availability of supporting data
Sequences are available from the NCBI short read archive
(accession no. SRP041565). Primer sequences not provided
in Additional file 5 are available on request.
Methods
Mouse infection and splinkerette-based PCR mapping of
integrations
Inbred BALB/c and NMRI mice were infected with the
rapid lymphomagenic MLV SL3-3 strain as described
previously [48-50]. Upon disease or appearance of tumors
(in 60 to 70 days) the mice were sacrificed and spleen and
thymus organs eviscerated and kept frozen at −80°C. The
approx. size of thymic tumors was ~1.5 cm in the longest
dimension while that of splenic tumors was ~3 cm. DNA
was extracted using the DNeasy Tissue kit (Qiagen)
and integrations determined using an automated high-
throughput splinkerette-PCR method [36,38]. We have
previously published results from the screen of ~2,000
BALB/c mice (Table 1). The NMRI dataset in Additional
file 3 contains integrations from several cohorts of mice
infected with SL3-3. The total number of mice was 120,
including a cohort of 22 mice from which the four tumors
subjected to RNA-seq originate.
RNA isolation
Total RNA was extracted from thymus and spleen by
the guanidinium thiocyanate-phenol-chloroform method
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the RNeasy Mini Kit (Qiagen), including on-column
DNase I treatment (Qiagen), and stored at −80°C. The
concentration and purity was routinely determined on a
NanoDrop (Thermo Scientific), and RNA integrity was
assessed by microfluidics technology on the Agilent
BioAnalyzer 2100 (Agilent).
cDNA library preparation and sequencing
Total RNA from four SL3-3-induced NMRI mouse tumors
was depleted of rRNA by hybridization using Ribo-Zero
rRNA Removal Kit for Human/Mouse/Rat (Epicentre).
The samples were then concentrated with RNA Clean &
Concentrator (Zymo Research), and cDNA libraries pre-
pared with the ScriptSeq RNA-Seq Library Preparation
Kit (Epicentre) following the manufacturer’s guidelines.
The libraries incorporated barcodes for multiplexed se-
quencing using the RNA-Seq Barcode Primers for Illu-
mina (Epicentre). The resulting cDNA libraries were
amplified by limited 12-cycle PCR and size-fractionated
using high-percentage agarose gel electrophoresis. The
size of the sequenced libraries was 400–450 bp including
adaptors. The libraries were selectively quantified on a
LightCycler 480 II Real-Time PCR System (Roche), using
the KAPA Library Quantification Assay (Kapa Biosystems).
The libraries were pooled in equal amounts on one paired-
end flow cell lane using the cBot cluster generation process
(Illumina), and sequenced on an Illumina HiSeq 2000 pro-
ducing 2x101-base sequencing reads.
RNA-seq-based integration mapping
To filter chimeric read pairs a custom reference was
built manually using BLAT [99] based on the content of
SL3-3 LTR-like sequence in the NCBIM37/mm9 mouse
reference assembly (Additional file 1: Figure S8). In brief,
SL3-3 LTR [GenBank:AF169256] sequence windows
were aligned to the mouse genome in 5 bp increments
to identify mouse sequence windows showing 90% or
higher identity by sequence. The custom reference in-
cluded also SL3-3 sequences [GenBank:X00862 and
GenBank:AF169256]. Subsequently, 25 bp sequencing
reads were mapped against the custom reference with
the Burrows-Wheeler Aligner (BWA) [100] followed by
sequestration of read pairs in which only one of the mates
mapped. To identify integrations full length reads were
quality trimmed and aligned separately with BLAT against
the NCBIM37/mm9 reference assembly modified to con-
tain SL3-3 on a separate chromosome. The chimeric pairs
produce either one of 14 paired-end sequence signatures,
based on U3, U5, SD or no chimeric fusion coverage
(Additional file 1: Figure S1). We manually examined the
evidence for each of the integrations and integrations
common to the samples were considered endogenous
false-positives based on the improbability of insertion atthe exact same position in several samples. Integrations
supported by a chimeric fusion contained intact sequence,
at one or both LTRs. In any case the minimum require-
ment was 40 bp of unambiguously mapped sequence. The
integrations are listed in Additional file 2.
Analysis of ENCODE data
ChIP-seq data [25] were obtained from ENCODE
(Additional file 1: Figure S4), while SL3-3 integrations
were obtained from the screens of NMRI and BALB/c
mice shown in Table 1. We determined the colocalization
of integrations in end-stage tumors with enhancers using
complete (n = 6,117) and reduced (n = 2,127) integration
datasets. The analyses were performed using BEDTools
[53]. As control size-matched random datasets were used
in iterative simulations (n = 1,000) for each analysis shown
in Figure 5. In brief, the ChIP-seq datasets were annotated
according to UCSC TSS annotations, excluding unmap-
pable sequence. The median peak length and sequence
content (the size in bp) of each dataset within the searched
genome was then used for picking random intervals with-
out replacement from NCBIM37/mm9. We defined direct
overlaps based on extension of ChIP-seq peaks by 1,250 bp.
In each case intersection was performed using 1 bp integra-
tion coordinates. The determination of empirical p-values
based on random sampling was performed as previously
described [101]. The reduced SL3-3 integration dataset was
assembled by clustering integrations in bins of 2,500 bp
across the genome. Clusters larger than this (containing
more than two integration positions) were excluded.
The position of integrations for clusters that contained
more than one integration site was defined as the cluster
midpoint. Out of the 2,127 coordinates in the reduced
integration dataset 1,981 (93%) represented individual
integration sites.
Sequence alignment, visualization and expression
analysis
FASTQ files were processed including adapter clipping
and quality trimming, and aligned to the NCBI37/mm9
mouse assembly with Bowtie/TopHat [102]. The visuali-
zations in Figures 2 and 4, as well as Additional file 1:
Figures S2-S3 are based on forward read alignments for
which the sequence coverage of each sample was com-
puted strand-specifically with BEDTools [53] and scaled
using Cufflinks library metrics [47]. The images were
generated using the UCSC Genome Browser and post-
processed using standard vector imaging tools. The
remapping of Celf2 in Figure 4E was performed using
Celf2 (chr2:6,453,742-7,029,527) and the SL3-3 pro-
viral sequence (built using [GenBank:X00862, GenBank:
AF169256]) inserted at the predetermined integration site
(Additional file 2) including also the TSD. The Cufflinks
transcript expression values for the loci shown in Figure 2,
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Additional file 4.
DNA analysis, RT-PCR, qPCR, RACE and cloning
DNA and RNA were copurified with TRIzol (Invitrogen)
followed by DNA back-extraction and clean-up using
QIAamp spin columns (Qiagen). To confirm integrations
(Figure 1E) 40 ng of genomic DNA was subjected to
40 cycles of PCR (DreamTaq, Thermo Scientific) using
three or more primer pairs designed to yield products
of size differences discernible by gel electrophoresis
(Additional file 1: Figure S9). In case a distinct band
pattern did not appear select products were Sanger se-
quenced (described below). For RT-PCR and the qPCR-
results shown in Figure 3 primer sequences from OriGene
were used with exceptions. 500 ng of RNA was used for
cDNA synthesis with the qScript cDNA SuperMix
(Quanta Biosciences). PCR-reactions (DreamTaq, Thermo
Scientific) were performed in a 2720 Thermo Cycler
(Applied Biosystems) using standard cycling conditions,
i.e. annealing at Tm -5°C. For qPCR measurements a
Stratagene Mx3000P cycler was used (Applied Biosciences).
Samples were measured in duplicates using PerfeCta SYBR
Green FastMix (Quanta Biosciences) in 10 μL reactions,
and beta-actin as reference. As controls, tumors were used
without known integrations at the loci shown in Figure 2
and included for tumors not subjected to RNA-seq a mini-
mum of three samples from the same mouse strain (BALB/
c or NMRI) and tissue (thymus or spleen). Above-threshold
values were defined as Ct values greater than 30 cycles of
amplification. RACE was carried out using the SMARTer
RACE cDNA amplification Kit (Clontech) in nested reac-
tions. cDNA synthesis for 5′-RACE included random
priming, and was performed according to manufacturer’s
guidelines. For Sanger sequencing PCR products were
cloned in the pCR4-TOPO vector using the TOPO TA
Cloning Kit for Sequencing (Invitrogen). The primers used
in this study are shown in Additional file 5.
Additional files
Additional file 1: Figure S1. Paired-end RNA-seq signatures expose
retroviral integration sites. Figure S2. The Tmem30b/Prkch locus is
deregulated by a bidirectional-type activation mechanism. Figure S3.
Integration in Wwox induces overexpression of distal Maf and activation of
unannotated transcription outside Wwox. Figure S4. ChIP-seq datasets from
ENCODE. Figure S5. Integrations in end-stage tumors form clusters at
immediate, intermediate and distal positions from TSSs. Figure S6.
Chromosomal distributions of promoter-distal integrations in the
complete and reduced integration datasets. Figure S7. Distribution of
colocalizing integrations with respect to H3K4Me1 and H3K27Ac ChIP-seq
peaks from spleen and thymus. Figure S8. Content of SL3-3 LTR-like sequence
in the mouse genome assembly (NCBIM37/mm9). Figure S9. PCR
confirmation of integrations identified in RNA sequencing.
Additional file 2: Integrations identified using RNA-seq. In columns
2–3 the integrations for each tumor are numbered according to
Figures 1C to E. The positions and orientations (sense, S and antisense,AS) of the integrations with respect to the reference genome, and the
presence (+) or absence (−) of chimeric fusions are shown in columns
4–8. In cases the chimeric fusion point was not covered in sequencing, the
integration positions correspond to the 5′-end of the murine read mates. In
columns 9–12 the distance of integrations to the nearest RefSeq annotation
are shown as well as the positions of proviruses (exon, intron, or outside).
Columns 13–15 show if the genes have been tagged (+) or not (−) in the
RTCGD or in screens of BALB/c and NMRI mice (described in the main text).
The distance of the RNA-seq integrations to the nearest integrations from
these screens is indicated in column 16. The four tumors (324 through 410)
had also been analyzed in the NMRI mouse screen. Seven out of 13
integrations identified in the latter screen were detected with deep
sequencing (Additional files 2 and 3, compared). The analyses were
performed on different tumor sections.
Additional file 3: Integrations identified in NMRI mice using
splinkerette-based PCR. The dataset contains integrations from several
cohorts of NMRI mice infected with SL3-3 including a cohort of 20 mice
from which the four mouse tumors (324 through 410) subjected to RNA-seq
originate (described in Methods). The integrations are sorted in order of
decreasing number of tags at a locus. The first column shows tumors
used in the present study for RNA-seq and/or qPCR and RACE. The layout
column shows the orientations of integrations with respect to the genes:
e.g. at chr5:108,167,153 the provirus is located 6,660 bp downstream from
Evi5 in the opposite (antisense) orientation relative to this gene.
Additional file 4: RNA-seq transcript expression values. This table
lists Cufflinks fragments per kilobase of transcript per million mapped
reads (FPKM) [47] values using the UCSC mouse transcriptome prediction
track for the deregulated loci described in the manuscript. The lower
(conf_lo) and upper (conf_hi) bounds of the 95% confidence interval of
transcript abundances is also indicated. The complete RNA-seq data is
available online.
Additional file 5: Primer sequences. For the DNA analyses the mouse
primer sequences are available upon request.Abbreviations
MLV: Murine leukemia virus; IM: Insertional mutagenesis; LTR: Long terminal
repeat; CIS: Common integration site; RNA-seq: RNA sequencing;
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